NCT00534144已完成1 期
A Randomized Controlled Trial of the Effect of IV Iron on Proteinuria in Non-Dialysis Chronic Kidney Disease Patients
Watson Pharmaceuticals0 个研究点目标入组 74 人开始时间: 2007年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 74
- 主要终点
- Change in urine protein
研究概览
简要总结
This study will compare the effects of sodium ferric gluconate complex and iron sucrose on urine concentrations of various chemicals including protein
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Moderate to severe anemia
- •Iron deficiency
- •Moderate to severe chronic kidney disease, not receiving dialysis
- •Age ≥ 18 or greater and able to give informed consent
排除标准
- •Known sensitivity to Sodium Ferric Gluconate Complex in Sucrose Injection, Iron sucrose USP, or any of their components
- •Clinically unstable
- •Indication of iron sufficiency
- •Bladder obstruction conditions that would not allow for good urine output
研究组 & 干预措施
Iron Sucrose
Active Comparator
干预措施: iron sucrose injection, USP (Drug)
Ferric Gluconate
Active Comparator
干预措施: sodium ferric gluconate complex in sucrose injection (Drug)
结局指标
主要结局
Change in urine protein
时间窗: 6 weeks
次要结局
未报告次要终点
研究者
相似试验
已完成
4 期
Effect of Two Iron Preparations on Protein in the UrineAnemia, Iron-DeficiencyKidney Failure, ChronicNCT00354692Watson Pharmaceuticals12
已完成
4 期
IV Iron in Acute Decompensated Heart FailureHeart FailureNCT04063033Rambam Health Care Campus34
Unknown
4 期
Iron Therapy in Colo-Rectal Neoplasm and Iron Deficiency Anemia: Intravenous Iron Sucrose Versus Oral Ferrous Sulphate.Colorectal NeoplasmIron Deficiency AnemiaNCT00199277J. Uriach and Company150
撤回
不适用
Effects of Iron Therapy and Exercise Training in Patients With Heart Failure and Iron DeficiencyHeart Failure With Reduced Ejection FractionExercise TrainingFerric CarboxymaltoseNCT03803111Herzzentrum Bremen
已完成
4 期
Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic AgentsAnemia, Iron-DeficiencyKidney Failure, ChronicNCT00224042Watson Pharmaceuticals52
